Atrial Flutter
173
22
31
93
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
28 trials with published results (16%)
Research Maturity
93 completed trials (54% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.1%
14 terminated out of 173 trials
86.9%
+0.3% vs benchmark
23%
39 trials in Phase 3/4
30%
28 of 93 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 93 completed trials
Clinical Trials (173)
International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry
Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures
Anatomical Navigation for Guided Electrophysiology in AFL and AFib
Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
HeartBeam ECG Registry
Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation
Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease
Cardiologist-Administered Midazolam vs. Anaesthesiologist-Assisted Propofol Sedation For Transoesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation
Baseline Atrial Fibrosis Predicts Risk for Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)
Acute Atrial Fibrillation and Flutter Treated Electively
Home Monitor for AA Burden Detection IIT in TWN
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation
A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form
Impact of Catheter Ablation on ABC Risk Scores
Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation
Pulsed-Field Ablation for Recurrent Atypical Atrial Flutter